ARB 301
Alternative Names: ARB-301Latest Information Update: 28 Oct 2025
At a glance
- Originator Arbele
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Pancreatic cancer
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for preclinical development in Colorectal-cancer(Metastatic disease) in Hong Kong (Parenteral)
- 28 Oct 2025 No recent reports of development identified for preclinical development in Pancreatic-cancer(Late-stage disease) in Hong Kong (Parenteral)
- 04 Oct 2023 ARB 301 is still in preclinical trials for Colorectal-cancer (Metastatic disease) in Hong Kong (Arbele pipeline, October 2023)